Scroll to top

Morning Rounds: Is it time to jump into biotech?

No comments

Is it time to jump into biotech?

What a year 2019 has been so far! We began the year with a bang. Biopharma M&A was has been front and center following BMY’s proposed $70 Billion USD acquisition of CELG. This seems to have triggered others to spring to action, as Eli Lilly announced to buy Loxo Oncology for about $8 Billion USD in cash thus gaining access to a portfolio of targeted medicines to treat cancers. This offer was about 68% premium of Loxo’s Friday close at $235/share.

Despite slowing topline growth and significant post-tax reform firepower for numerous large-cap biopharma companies which supports M&A potential, one must point to the stock reactions for recent acquirers, notably GSK (-8% post TSRO offer), BMY (-14% post CELG offer) and LLY (-2% post LOXO offer). While this may be true, we still remain optimistic for M&As to continue in 2019, we urge you to consider drug pricing uncertainty in addition to recent volatility into your models.

In light of this M&A theme following the BMY/CELG announcement, we recommend keeping an eye on following the capital allocation commentary from AMGN, BIIB and GILD. Below, we provide our guidance on our top watchlist for the month of January. Specific dates and catalysts are provided for the following stocks,  SRPT, INSP, SLDB, EXEL, and IMMU. 

The remaining of this post is for our members only. User the Promo Code “INVEST” for a 75% discount. Our student discount – our new years’ gift to our readers. 

Author avatar

Dr. Tiam Feridooni

Written by: Dr. Tiam Feridooni MD, PhD, BSc Dr. Feridooni, graduated from Dalhousie Medical School in May, 2018. Prior to enrolling in medical school, he completed his Bachelor of Science with Honours in 2010 in Biochemistry. He then obtained his PhD at Dalhousie University in Pharmacology in 2014, with a focus around regenerative medicine and stem cell transplantation. Dr. Feridooni has been published numerous high impact journals and has also co-authored a few books.

Related posts